
Colorectal Cancer
Latest News
Latest Videos

More News

The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency.

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic colorectal cancer to begin.

Writing helped me focus on gratitude and healing after my colon cancer diagnosis, transforming the act into a powerful recovery tool.

Three of five patients with advanced colorectal cancer responded to leronlimab, including one complete response lasting five years, according to new data.

Press Release
The Colorectal Cancer Alliance initiative is bridging gaps in cancer care progress with grants totaling almost $12 Million.

Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic colorectal cancer, phase 3 data show.

Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.

Press Release
Alliance survey reveals most Americans deprioritize colorectal cancer screening, yet screening & innovative research are critical to survivorship.

Braftovi and Erbitux plus chemotherapy improved survival without progression over standard therapy in BRAF V600E-mutant mCRC in the first-line setting.

Tumors shrank more with the addition of acoustic cluster therapy to chemotherapy in colorectal liver metastases in the phase 1 ACTIVATE trial.

As a Lynch syndrome previvor, I feel deep gratitude to witness my son’s graduation — a milestone my brother never lived to see with his own child.

Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer with a BRAF V600E mutation.

Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic colorectal cancer.

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types.

LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, according to UCLA researchers.


The Oncodetect test detects molecular residual disease across solid tumors using circulating tumor DNA to inform recurrence risk and treatment decisions.

The first patient has received TCMCB07 in a phase 2 trial to prevent weight loss in patients with metastatic colorectal cancer undergoing chemotherapy.

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

Living with Lynch isn't easy, but it's not all doom and gloom. It's a call to live deliberately.

Press Release
Alliance advocates for greater awareness during April minority health month.

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.

I always wanted to make a difference, but I never expected my biggest impact to come through cancer.

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.














